Obesity Risk

A new report analysing over 400,000 employees reveals rising risks of diabetes, obesity and heart disease, often without symptoms, pointing to a growing preventive healthcare gap in India

Global drugmakers are prioritising China and Japan for GLP-1 investments due to stronger pricing power and adoption, while India remains a large but price-sensitive market with slower premium uptake

Body weight is biologically regulated, and targeting the right biological pathways can lead to meaningful weight loss that can help transform lives

As muscle mass declines and abdominal fat rises with age, BMI can be misleading. A new study finds waist-to-height ratio better reflects real obesity risk in older adults

Entry of generics post March 2026, patient dropouts to affect sales values, say experts

Researchers warn that the findings reflect a growing global health crisis, as outdated BMI standards fail to capture hidden fat-linked risks contributing to chronic disease.

As digital dependency grows, experts warn that prolonged screen time is taking a toll on posture, sleep, and overall health, with many of its effects deeply interconnected

The company initially plans to launch the generic version in Canada, India, Brazil, Turkey and other emerging markets, subject to patent expiry, Israeli said at a press conference

India's Rs 628-crore anti-obesity market sees heightened competition as Wegovy and Mounjaro post strong sales amid rising obesity and growing doctor awareness

Mounjaro has sold more than 81,570 units in India, totalling about ₹23.94 crore ($2.76 million) as of May, with the drug logging a 60 per cent rise in overall sales between April and May

Delhi High Court bars Dr Reddy's and OneSource from selling semaglutide in India, supporting Novo Nordisk's patent rights as it fast-tracks Wegovy launch amid growing obesity drug demand

We Indians have had a different perspective around obesity

Lilly's rival Danish firm Novo Nordisk is also working to bring its obesity drug Wegovy (Semaglutide) to India soon, and according to reports the company may launch Wegovy in 2026

The company's s blockbuster weight-loss and diabetes drugs have made it the most valuable pharmaceutical company in the world

Expanding coverage of weight-loss drugs like blockbusters from Eli Lilly & Co. and Novo Nordisk A/S would make 12.5 million more people in the US program eligible

Infertility is not just a medical condition but a crisis fuelled by lifestyle choices, with infertility rates soaring particularly in lower-income groups and tier 2 and 3 cities where access to healthcare is limited, a top IVF specialist said. Dr Ajay Murdia, the man behind one of India's largest fertility chain, Indira IVF, said while advancements in assisted reproductive technologies like In Vitro Fertilization (IVF) offer hope, it is a reality that the underprivileged who are hit hard. "Infertility rates are soaring, particularly in lower-income and tier 2 and 3 cities, where access to healthcare, nutrition, and education is limited," Dr Murdia, founder and chairman of Indira IVF, told PTI. "Infertility is no longer just a medical issue; it's a crisis fuelled by lifestyle choices that hit the underprivileged hardest. Without action, even advancements like IVF will remain out of reach for many," he said. Lifestyle factors such as obesity, poor diet, smoking, and chronic stress, .

From 2007 to 2021, obesity-related cancer rates in China rose by 3.6% annually, with a striking 15.3% increase for those aged 25 to 29, while rates for non-obesity-linked cancers stayed stable

The Danish company lowered its forecast for operating profit growth this year to between 20% and 28% in local currencies, compared to its previous forecast of 22% to 30%

Obesity can no longer be just defined by body mass index (BMI) and rather should be about how body fat is distributed throughout one's body, researchers said while launching a new framework for diagnosing and managing obesity. Published in the journal Nature Medicine, the framework looks specifically at fat accumulated in the abdomen, measured as 'waist-to-height ratio' -- an increased value of which is related to a higher risk of developing cardiometabolic complications, according to the researchers. An "important novelty" of the framework is including a waist-to-height ratio higher than 0.5, along with a BMI of 25-30, for diagnosing obesity, the authors, representing the European Association for the Study of Obesity (EASO), said. "The choice of introducing waist-to-height ratio, instead of waist circumference, in the diagnostic process is due to its superiority as a cardiometabolic disease risk marker," they wrote. Accumulation of abdominal fat is a more reliable predictor of hea

The company, helmed by Kiran Mazumdar Shaw, is leading the charge among Indian drugmakers - the world's largest supplier of generic medicines - as they race to grab a slice of the obesity drugs market